Absci's ABS-201 Phase 1 Data De-Risks Hair Loss Program Ahead of Efficacy Readout, Truist Says

MT Newswires Live06-25 03:02

Absci's (ABSI) ABS-201 showed a favorable early safety profile, with no serious adverse events, and pharmacokinetic data supporting a potential two- to three-injection regimen over six months, Truist said in a note on Wednesday.

ABS-201 is an anti-prolactin receptor antibody being developed for the treatment of androgenetic alopecia.

Truist said the interim phase 1 results represent a de-risking event for the program and that it is now looking ahead to proof-of-concept efficacy data expected in H2.

The convenience of that dosing schedule, if supported by future efficacy readouts, could position ABS-201 as a preferred option in the hair growth space, the note said.

Truist kept its Buy rating and $11 price target on the stock.

Shares of Absci surged 35% in Wednesday afternoon trading.

Price: 10.02, Change: +2.61, Percent Change: +35.22

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646684841?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 03:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646684841","market":"us","top_or_hot":-1,"title":"Absci's ABS-201 Phase 1 Data De-Risks Hair Loss Program Ahead of Efficacy Readout, Truist Says","media":"MT Newswires Live","content":"<html><body><p> Absci's (ABSI) ABS-201 showed a favorable early safety profile, with no serious adverse events, and pharmacokinetic data supporting a potential two- to three-injection regimen over six months, Truist said in a note on Wednesday.</p><p>ABS-201 is an anti-prolactin receptor antibody being developed for the treatment of androgenetic alopecia.</p><p>Truist said the interim phase 1 results represent a de-risking event for the program and that it is now looking ahead to proof-of-concept efficacy data expected in H2.</p><p>The convenience of that dosing schedule, if supported by future efficacy readouts, could position ABS-201 as a preferred option in the hair growth space, the note said.</p><p>Truist kept its Buy rating and $11 price target on the stock.</p><p>Shares of Absci surged 35% in Wednesday afternoon trading.</p><p>Price: 10.02, Change: +2.61, Percent Change: +35.22</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Absci's ABS-201 Phase 1 Data De-Risks Hair Loss Program Ahead of Efficacy Readout, Truist Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbsci's ABS-201 Phase 1 Data De-Risks Hair Loss Program Ahead of Efficacy Readout, Truist Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-25 03:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Absci's (ABSI) ABS-201 showed a favorable early safety profile, with no serious adverse events, and pharmacokinetic data supporting a potential two- to three-injection regimen over six months, Truist said in a note on Wednesday.</p><p>ABS-201 is an anti-prolactin receptor antibody being developed for the treatment of androgenetic alopecia.</p><p>Truist said the interim phase 1 results represent a de-risking event for the program and that it is now looking ahead to proof-of-concept efficacy data expected in H2.</p><p>The convenience of that dosing schedule, if supported by future efficacy readouts, could position ABS-201 as a preferred option in the hair growth space, the note said.</p><p>Truist kept its Buy rating and $11 price target on the stock.</p><p>Shares of Absci surged 35% in Wednesday afternoon trading.</p><p>Price: 10.02, Change: +2.61, Percent Change: +35.22</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2646684841","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646684841","pubTimestamp":1782327725,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Absci's  ABS-201 showed a favorable early safety profile, with no serious adverse events, and pharmacokinetic data supporting a potential two- to three-injection regimen over six months, Truist said in a note on Wednesday.ABS-201 is an anti-prolactin receptor antibody being developed for the treatment of androgenetic alopecia.Truist said the interim phase 1 results represent a de-risking event for the program and that it is now looking ahead to proof-of-concept efficacy data expected in H2.The convenience of that dosing schedule, if supported by future efficacy readouts, could position ABS-201 as a preferred option in the hair growth space, the note said.Truist kept its Buy rating and $11 price target on the stock.Shares of Absci surged 35% in Wednesday afternoon trading.Price: 10.02, Change: +2.61, Percent Change: +35.22","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","ABSI":"Absci Corporation.","BK4121":"生命科学工具和服务"},"translate_title":"Truist表示，Absci的ABS-201 1期数据在疗效读数之前降低了脱发计划的风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABSI":1},"content_text":"Absci's (ABSI) ABS-201 showed a favorable early safety profile, with no serious adverse events, and pharmacokinetic data supporting a potential two- to three-injection regimen over six months, Truist said in a note on Wednesday.ABS-201 is an anti-prolactin receptor antibody being developed for the treatment of androgenetic alopecia.Truist said the interim phase 1 results represent a de-risking event for the program and that it is now looking ahead to proof-of-concept efficacy data expected in H2.The convenience of that dosing schedule, if supported by future efficacy readouts, could position ABS-201 as a preferred option in the hair growth space, the note said.Truist kept its Buy rating and $11 price target on the stock.Shares of Absci surged 35% in Wednesday afternoon trading.Price: 10.02, Change: +2.61, Percent Change: +35.22","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646684841","isCrawlerRequest":true}